Inovio Pharmaceuticals IncFind Ratings Reports
INOVIO PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. INOVIO PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 4.08 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 10.28% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY16||Q2 FY15|
|Net Sales ($mil)||6.2||5.29|
|Net Income ($mil)||-18.71||-6.25|
|Balance Sheet||Q2 FY16||Q2 FY15|
|Cash & Equiv. ($mil)||134.53||154.59|
|Total Assets ($mil)||203.99||201.7|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q2 FY16||Q2 FY15|
|Gross Profit Margin||-297.23||-296.31|
|Return on Assets||-19.17||-15.57|
|Return on Equity||-24.14||-17.4|
|Debt||Q2 FY16||Q2 FY15|
|Share Data||Q2 FY16||Q2 FY15|
|Shares outstanding (mil)||73.48||71.81|
|Div / share||0.0||0.0|
|Book value / share||2.2||2.51|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1190215.0||1669890.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Conducting a second comparison, its price-to-book ratio of 3.97 indicates a premium versus the S&P 500 average of 2.72 and a significant discount versus the industry average of 9.92. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, INOVIO PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.
|INO NM||Peers 41.54||INO NM||Peers 20.57|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
INO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
INO's P/CF is negative making the measure meaningless.
|INO NM||Peers 32.83||INO NA||Peers 0.46|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
INO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|INO 3.97||Peers 9.92||INO -7.84||Peers -0.63|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
INO is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, INO is expected to significantly trail its peers on the basis of its earnings growth rate.
|INO 14.47||Peers 562.15||INO 201.24||Peers 51.41|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
INO is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
INO has a sales growth rate that significantly exceeds its peers.